China Oncology ›› 2025, Vol. 35 ›› Issue (4): 339-345.doi: 10.19401/j.cnki.1007-3639.2025.04.001
• Specialist's Commentary • Previous Articles Next Articles
Received:
2024-12-30
Revised:
2025-03-31
Online:
2025-04-30
Published:
2025-05-16
Contact:
MA Li
Supported by:
Share article
ZHANG Yujia, MA Li. Advances and controversies in emerging techniques of surgery on breast cancer[J]. China Oncology, 2025, 35(4): 339-345.
[1] | NANDA A, HU J, HODGKINSON S, et al. Oncoplastic breast-conserving surgery for women with primary breast cancer[J]. Cochrane Database Syst Rev, 2021, 10(10): CD013658. |
[2] |
MAGNONI F, GALIMBERTI V, CORSO G, et al. Axillary surgery in breast cancer: an updated historical perspective[J]. Semin Oncol, 2020, 47(6): 341-352.
doi: 10.1053/j.seminoncol.2020.09.001 pmid: 33131896 |
[3] |
SCHEEPENS J C C, VAN 'T VEER L, ESSERMAN L, et al. Contralateral prophylactic mastectomy: a narrative review of the evidence and acceptability[J]. Breast, 2021, 56: 61-69.
doi: 10.1016/j.breast.2021.02.003 pmid: 33621798 |
[4] | JI H R, HU C, YANG X H, et al. Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions[J]. Signal Transduct Target Ther, 2023, 8(1): 367. |
[5] | THOMPSON J L, PAUL WRIGHT G. Contemporary approaches to the axilla in breast cancer[J]. Am J Surg, 2023, 225(3): 583-587. |
[6] | GIULIANO A E, BALLMAN K V, MCCALL L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (alliance) randomized clinical trial[J]. JAMA, 2017, 318(10): 918-926. |
[7] |
DONKER M, VAN TIENHOVEN G, STRAVER M E, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial[J]. Lancet Oncol, 2014, 15(12): 1303-1310.
doi: 10.1016/S1470-2045(14)70460-7 pmid: 25439688 |
[8] | DE BONIFACE J, TVEDSKOV T F, RYDÉN L, et al. Omitting axillary dissection in breast cancer with sentinel-node metastases[J]. N Engl J Med, 2024, 390(13): 1163-1175. |
[9] | TRIPATHI M, VINEET K. SENOMAC trial: The devil is in the details[J]. Indian J Surg Oncol, 2024, 15(4): 693. |
[10] | BRACKSTONE M, BALDASSARRE F G, PERERA F E, et al. Management of the axilla in early-stage breast cancer: Ontario health (cancer care Ontario) and ASCO guideline[J]. J Clin Oncol, 2021, 39(27): 3056-3082. |
[11] | GRADISHAR W J, MORAN M S, ABRAHAM J, et al. Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2024, 22(5): 331-357. |
[12] |
中国抗癌协会乳腺癌专业委员会, 中华医学会肿瘤学分会乳腺肿瘤学组. 中国抗癌协会乳腺癌诊治指南与规范(2024年版)[J]. 中国癌症杂志, 2023, 33(12): 1092-1187.
doi: 10.19401/j.cnki.1007-3639.2023.12.004 |
The Society of Breast Cancer China Anti-Cancer Association, Breast Oncology Group of the Oncology Branch of the Chinese Medical Association. Guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2024 edition)[J]. Chin Oncol, 2023, 33(12): 1092-1187.
doi: 10.19401/j.cnki.1007-3639.2023.12.004 |
|
[13] |
《中国乳腺癌新辅助治疗专家共识(2022年版)》专家组. 中国乳腺癌新辅助治疗专家共识(2022年版)[J]. 中国癌症杂志, 2022, 32(1): 80-89.
doi: 10.19401/j.cnki.1007-3639.2022.01.011 |
Expert group of expert consensus on neoadjuvant treatment of breast cancer in China (2022 edition). Expert consensus on neoadjuvant treatment of breast cancer in China (2022 edition)[J]. Chin Oncol, 2022, 32(1): 80-89.
doi: 10.19401/j.cnki.1007-3639.2022.01.011 |
|
[14] | DETZ D Jr, HANSSEN D, WHITING J, et al. Retrieval of the clipped axillary lymph node and its impact on treatment decisions[J]. Cancers (Basel), 2024, 16(17): 3001. |
[15] | SUN X, WANG X E, ZHANG Z P, et al. Neoadjuvant therapy and sentinel lymph node biopsy in HER2-positive breast cancer patients: results from the PEONY trial[J]. Breast Cancer Res Treat, 2020, 180(2): 423-428. |
[16] | SWARNKAR P K, TAYEH S, MICHELL M J, et al. The evolving role of marked lymph node biopsy (MLNB) and targeted axillary dissection (TAD) after neoadjuvant chemotherapy (NACT) for node-positive breast cancer: systematic review and pooled analysis[J]. Cancers (Basel), 2021, 13(7): 1539. |
[17] |
MONTAGNA G, MRDUTT M M, SUN S X, et al. Omission of axillary dissection following nodal downstaging with neoadjuvant chemotherapy[J]. JAMA Oncol, 2024, 10(6): 793-798.
doi: 10.1001/jamaoncol.2024.0578 pmid: 38662396 |
[18] |
KANAIZUMI H, HIGASHI C, TANAKA Y, et al. PI3K/AKT/mTOR signalling pathway activation in patients with ER-positive, metachronous, contralateral breast cancer treated with hormone therapy[J]. Oncol Lett, 2019, 17(2): 1962-1968.
doi: 10.3892/ol.2018.9759 pmid: 30675261 |
[19] | YE F G, HUANG L, LANG G T, et al. Outcomes and risk of subsequent breast events in breast-conserving surgery patients with BRCA1 and BRCA2 mutation[J]. Cancer Med, 2020, 9(5): 1903-1910. |
[20] | GONZÁLEZ-SANTIAGO S, RAMÓN Y CAJAL T, AGUIRRE E, et al. SEOM clinical guidelines in hereditary breast and ovarian cancer (2019)[J]. Clin Transl Oncol, 2020, 22(2): 193-200. |
[21] | NODITI A, CARAGHEORGHE G, STOLERU S, et al. Contralateral prophylactic mastectomy in patients with breast cancer[J]. Chirurgia (Bucur), 2021, 116(2 Suppl): 73-83. |
[22] |
SRETHBHAKDI A, BRENNAN M E, HAMID G, et al. Contralateral prophylactic mastectomy for unilateral breast cancer in women at average risk: systematic review of patient reported outcomes[J]. Psychooncology, 2020, 29(6): 960-973.
doi: 10.1002/pon.5379 pmid: 32201988 |
[23] | GIANNAKEAS V, LIM D W, NAROD S A. Bilateral mastectomy and breast cancer mortality[J]. JAMA Oncol, 2024, 10(9): 1228-1236. |
[24] | KHAN S A, KOCHERGINSKY M. Contralateral breast cancer remains a complex biologic conundrum[J]. JAMA Oncol, 2024, 10(9): 1175-1177. |
[25] | ARUN B N, COUCH F J, ABRAHAM J, et al. BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing[J]. Br J Cancer, 2024, 131(9): 1400-1414. |
[26] | ALLEN I, HASSAN H, WALBURGA Y, et al. Second primary cancer risks after breast cancer in BRCA1 and BRCA2pathogenic variant carriers[J]. J Clin Oncol, 2025, 43(6): 651-661. |
[27] | SU L M, XU Y, OUYANG T, et al. Contralateral breast cancer risk in BRCA1 and BRCA2mutation carriers in a large cohort of unselected Chinese breast cancer patients[J]. Int J Cancer, 2020, 146(12): 3335-3342. |
[28] | CHAI C S, HELENA WU H, ABUETABH Y, et al. Regulation of the tumor suppressor PTEN in triple-negative breast cancer[J]. Cancer Lett, 2022, 527: 41-48. |
[29] |
HUNT K K, EUHUS D M, BOUGHEY J C, et al. Society of surgical oncology breast disease working group statement on prophylactic (risk-reducing) mastectomy[J]. Ann Surg Oncol, 2017, 24(2): 375-397.
doi: 10.1245/s10434-016-5688-z pmid: 27933411 |
[30] | YADAV S, BODDICKER N J, NA J, et al. Contralateral breast cancer risk among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2[J]. J Clin Oncol, 2023, 41(9): 1703-1713. |
[31] | METCALFE K, HUZARSKI T, GRONWALD J, et al. Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2pathogenic variant: an international analysis[J]. Br J Cancer, 2024, 130(2): 269-274. |
[32] | CHEUN J H, KIM H K, MOON H G, et al. Locoregional recurrence patterns in patients with different molecular subtypes of breast cancer[J]. JAMA Surg, 2023, 158(8): 841-852. |
[33] | DALY M B, PILARSKI R, YURGELUN M B, et al. NCCN guidelines insights: genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 1.2020[J]. J Natl Compr Canc Netw, 2020, 18(4): 380-391. |
[34] | AKDENIZ D, MARIA KLAVER M, SMITH C Z A, et al. The impact of lifestyle and reproductive factors on the risk of a second new primary cancer in the contralateral breast: a systematic review and meta-analysis[J]. Cancer Causes Control, 2020, 31(5): 403-416. |
[35] | GIANNAKEAS V, LIM D W, NAROD S A. The risk of contralateral breast cancer: a SEER-based analysis[J]. Br J Cancer, 2021, 125(4): 601-610. |
[36] |
THEOBALD K A, SUSSWEIN L R, MARSHALL M L, et al. Utility of expedited hereditary cancer testing in the surgical management of patients with a new breast cancer diagnosis[J]. Ann Surg Oncol, 2018, 25(12): 3556-3562.
doi: 10.1245/s10434-018-6581-8 pmid: 30167906 |
[37] | 李梦欣, 范志民, 宋东. 中国家族遗传性乳腺癌行预防性乳房切除术临床实践指南(2024版)[J]. 中国实用外科杂志, 2024, 44(11): 1201-1205. |
LI M X, FAN Z M, SONG D. Guideline on the clinical practice for prophylactic mastectomy in hereditary breast cancer in China(2024 edition)[J]. Chin J Pract Surg, 2024, 44(11): 1201-1205. | |
[38] |
中国医师协会精准治疗委员会乳腺癌专业委员会, 中华医学会肿瘤学分会乳腺肿瘤学组, 中国抗癌协会乳腺癌专业委员会, 等. 中国乳腺癌患者BRCA1/2基因检测与临床应用专家共识(2018年版)[J]. 中国癌症杂志, 2018, 28(10): 787-800.
doi: 10.19401/j.cnki.1007-3639.2018.10.011 |
Breast Cancer Professional Committee of Precision Therapy Committee of Chinese Medical Doctor Association, Breast Cancer Group of Cancer Branch of Chinese Medical Association, the Society of Breast Cancer China Anti-Cancer Association, et al. Expert consensus on BRCA1/2 gene detection and clinical application of breast cancer patients in China (2018 edition)[J]. China Oncol, 2018, 28(10): 787-800. | |
[39] | CLEGG D J, WHITEAKER E N, SALOMON B J, et al. Contralateral prophylactic mastectomy in a rural population: a single-institution experience[J]. Surg Open Sci, 2024, 18: 70-77. |
[40] |
LIM D W, METCALFE K A, NAROD S A. Bilateral mastectomy in women with unilateral breast cancer: a review[J]. JAMA Surg, 2021, 156(6): 569-576.
doi: 10.1001/jamasurg.2020.6664 pmid: 33566074 |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd